Qurient acquires patent of Quinolinyloxyphenylsulfonamides related to cancer treatment

Published: 2017-07-14 10:44:00

Updated: 2017-07-14 10:44:00

Qurient gave an official notice on the 12^th that it acquired a patent of Quinolinyloxyphenylsulfonamides related to cancer treatment.

According to the company, the patent is about the core chemical structure of the anticancer immunity/resistance study and the use of its compound.(patentee: Max Planck Institutes in Germany)

Qurient said “The patent is a patent registered in Europe(Patent no. E...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.